Novartis AG Sponsored ADR (NVS)
Novartis to buy breast cancer drug candidate from Synnovation
Novartis said on Friday it agreed to acquire breast cancer drug candidate SNV4818 from Synnovation Therapeutics for $2 billion upfront and up to $1 billion contingent on further development achievements.
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
NVS wins CHMP backing for remibrutinib in chronic spontaneous urticaria, bringing its oral BTK inhibitor closer to EU approval.
Novartis, Genentech file suit alleging illegal importation of prescription drug
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine. The importation of the drug, which has strict shipping and temperature controls, potentially puts patients at risk, the suit said.
Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades
Novartis is a large drugmaker with a wide-ranging portfolio. Like all drugmakers, it faces the challenge of patent expirations.
Trump meets Novartis CEO, says drugmaker building 11 US plants
U.S. President Donald Trump said he met Vas Narasimhan, the chief executive officer of Swiss drugmaker Novartis , at the White House on Wednesday.
Novartis to sell entire 71% stake in Indian unit to consortium of WaveRise Investments
Swiss pharmaceutical firm Novartis said on Friday that it would sell its entire 70.68% stake in its listed Indian unit to a consortium of WaveRise Investments, ChrysCapital and Two Infinity Partners.
Unnatural Products, Novartis sign license deal worth up to $1.7 billion for cardiovascular program
Unnatural Products said on Wednesday it has signed a licensing agreement with Novartis to develop macrocyclic peptide-based therapies for a cardiovascular program.
NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia
Novartis posts positive phase III ALIGN data for Vanrafia in IgAN, showing slower kidney decline as it eyes full approval in 2026.
Novartis Says Vanrafia Drug Slows Kidney Function Decline
The pharma major said that phase 3 trials showed Vanrafia slowed the decline in kidney function for adults with progressive autoimmune kidney disease, IgA nephropathy.
Novartis: Value Price, Growth Pipeline
Novartis (NVS) offers a compelling value opportunity with EPS growth, margin expansion, and a robust pipeline at a discounted multiple. NVS is undergoing a slow re-rating, actively buying back shares, and expects seven key clinical readouts in the coming months. Q4 2025 showed strong core operating profit and margin, but revenue missed due to generic competition for Entresto and Promacta.
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
